Logo

Immunocore’s Kimmtrak (tebentafusp) Receives Approval for the Treatment of Unresectable Or Metastatic Uveal Melanoma in the UK, Australia, Canada

Share this
Immunocore’s Kimmtrak (tebentafusp) Receives Approval for the Treatment of Unresectable Or Metastatic Uveal Melanoma in the UK, Australia, Canada

Immunocore’s Kimmtrak (tebentafusp) Receives Approval for the Treatment of Unresectable Or Metastatic Uveal Melanoma in the UK, Australia, Canada

Shots:

  • The MHRA, TGA & Health Canada have granted marketing authorization for Kimmtrak to treat HLA-A*02:01+ adult patients with unresectable or mUM
  • The approvals were based on the results from the P-III (IMCgp100-202) trial evaluating Kimmtrak vs pembrolizumab, ipilimumab, or dacarbazine in a ratio (2:1) in 378 patients which showed an OS benefit with m-OS of 22mos., OS in the ITT population favored Kimmtrak compared to (82% pembrolizumab; 13% ipilimumab; 6% dacarbazine)
  • Patients also stopped taking treatment because of disease progression unless they were getting any other benefit, or for sev. toxicity, TRAEs were manageable & consistent with the proposed MoA, and no Grade 4 CRS events were reported

Ref: Globenewswire| Image: Immunocore

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions